RecruitingPhase 1NCT05892393

Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma

Sponsor

Robert Flavell, MD, PhD

Enrollment

20 participants

Start Date

Jun 16, 2023

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma Plasma Cell Myeloma

Summary

This phase I trial tests the safety of \[89Zr\]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. \[89Zr\]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. \[89Zr\]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and \[89Zr\]DFO-YS5 PET scans may improve detection of multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This imaging study uses a specialized PET scan to detect a protein called CD46 on myeloma cells throughout the body, which may help doctors better diagnose and track multiple myeloma. **You may be eligible if...** - You have a confirmed diagnosis of multiple myeloma using international criteria - At least one active myeloma lesion was found on a recent FDG PET scan **You may NOT be eligible if...** - You do not have confirmed multiple myeloma - No active lesions were detected on your prior PET scan Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZirconium Zr 89-DFO-YS5

Given IV

PROCEDUREPositron Emission Tomography / Computed Tomography (PET/CT)

Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image

PROCEDUREPositron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)

Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.

OTHERFludeoxyglucose F-18

Given IV